AstraZeneca Sets Aside $510M For Bristol-Myers Patent Deal
AstraZeneca has set aside $510 million to resolve Bristol-Myers Squibb Co.'s litigation that it infringed cancer treatment patents to create rival immunotherapy drugs, according to a recent securities filing....To view the full article, register now.
Already a subscriber? Click here to view full article